OncoSec Medical Incorporated (ONCS)’s Financial Results Comparing With Pfenex Inc. (NYSEAMERICAN:PFNX)

As Biotechnology businesses, OncoSec Medical Incorporated (NASDAQ:ONCS) and Pfenex Inc. (NYSEAMERICAN:PFNX), are affected by compare. This especially applies to their dividends, analyst recommendations, profitability, institutional ownership, risk, earnings and valuation.

Earnings and Valuation

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
OncoSec Medical Incorporated 4 0.00 N/A -6.08 0.00
Pfenex Inc. 6 10.74 N/A -1.09 0.00

Table 1 demonstrates OncoSec Medical Incorporated and Pfenex Inc.’s top-line revenue, earnings per share and valuation.


Table 2 represents OncoSec Medical Incorporated (NASDAQ:ONCS) and Pfenex Inc. (NYSEAMERICAN:PFNX)’s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
OncoSec Medical Incorporated 0.00% -149.9% -115.8%
Pfenex Inc. 0.00% -48.8% -37.5%

Volatility and Risk

OncoSec Medical Incorporated is 124.00% more volatile than Standard and Poor’s 500 due to its 2.24 beta. Pfenex Inc. on the other hand, has 2.29 beta which makes it 129.00% more volatile compared to Standard and Poor’s 500.


OncoSec Medical Incorporated’s Current Ratio and Quick Ratio are 5 and 5 respectively. The Current Ratio and Quick Ratio of its competitor Pfenex Inc. are 5 and 5 respectively. therefore has a better chance of paying off short and long-term obligations compared to .

Insider and Institutional Ownership

OncoSec Medical Incorporated and Pfenex Inc. has shares owned by institutional investors as follows: 17.3% and 83.6%. About 1.1% of OncoSec Medical Incorporated’s share are owned by insiders. Comparatively, Pfenex Inc. has 2.14% of it’s share owned by insiders.


Here are the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

Performance (W) Performance (M) Performance (Q) Performance (HY) Performance (Y) Performance (YTD)
OncoSec Medical Incorporated 1.36% -10.8% -60.16% -75.22% -82.3% -65.16%
Pfenex Inc. -2.65% -13.66% 3.34% 62.43% 16.44% 84.33%

For the past year OncoSec Medical Incorporated has -65.16% weaker performance while Pfenex Inc. has 84.33% stronger performance.


On 6 of the 6 factors Pfenex Inc. beats OncoSec Medical Incorporated.

OncoSec Medical Incorporated, a biotechnology company, designs, develops, and commercializes gene therapies, therapeutics, and proprietary medical approaches to stimulate and guide an anti-tumor immune response for the treatment of cancer in the United States. Its lead product candidate is the ImmunoPulse IL-12, which is in Phase II clinical trial for various indications, including metastatic melanoma and triple negative breast cancer. ImmunoPulse is an electroporation delivery device used in combination with the companyÂ’s therapeutic product candidates, including DNA plasmids that encode for immunologically active agents, and to deliver the therapeutic directly into the tumor and promote an inflammatory response against the cancer. The company also has completed two Phase II studies for products, such as OMS-I100 in metastatic melanoma and OMS-I110 in merkel cell carcinoma. It has a clinical collaboration with the University of California, San Francisco to evaluate the safety and efficacy of ImmunoPulse IL-12 in combination with KEYTRUDA (pembrolizumab) in patients with low tumor-infiltrating lymphocyte; and a clinical trial collaboration and supply agreement with MSD International GmbH to evaluate the combination of OncoSec's ImmuoPulse IL-12 with MerckÂ’s anti-PD-1 therapy KEYTRUDA (pembrolizumab) in a Phase II clinical trial referred to as PISCES. The company was formerly known as NetVentory Solutions Inc. and changed its name to OncoSec Medical Incorporated in March 2011. OncoSec Medical Incorporated was incorporated in 2008 and is headquartered in San Diego, California.

Pfenex Inc., a clinical-stage biotechnology company, develops biosimilar therapeutics in the United States. Its lead product candidates include PF708, a therapeutic equivalent candidate to Forteo (teriparatide) for the treatment of osteoporosis; PF582, a biosimilar to Lucentis (ranibizumab) for the treatment of patients with retinal diseases; and Px563L, a novel anthrax vaccine candidate in Phase 1a trial. The company also engages in developing a pipeline of additional biosimilar candidates, including PF529, a biosimilar candidate to Neulasta; PF688, a biosimilar candidate to Cimzia; PF530, a biosimilar candidate to Betaseron; PF690, a biosimilar candidate to the reference product Oncaspar; PF444-human growth hormone, a biosimilar candidate to Genotropin; and PF688-certolizumab-pegol, a biosimilar candidate to Cimzia. It has collaboration agreements with Hospira, Inc. and Jazz Pharmaceuticals Ireland Limited. Pfenex Inc. is headquartered in San Diego, California.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.